Literature DB >> 20615823

Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Blanca Homet Moreno1, Elena Garralda Cabanas, Ricardo Hitt.   

Abstract

Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a challenge. Advances in understanding the genetic nature of cancer have led to the development of new treatment options for sarcoma. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties and promising activity in the treatment of GIST refractory to imatinib, however in either soft tissue sarcoma, experience with sunitinib is under development in different clinical trials. In this review we offer the experience with this small molecular target in non-GIST sarcomas.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20615823     DOI： 10.1007/s12094-010-0539-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  37 in total

1.  Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.

Authors:  Amedeo A Azizi; Christine Haberler; Thomas Czech; Astrid Gupper; Daniela Prayer; Helene Breitschopf; Till Acker; Irene Slavc
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

2.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

Authors:  M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Authors:  Elena Tamborini; Francesca Miselli; Tiziana Negri; M Stefania Lagonigro; Samantha Staurengo; Gian Paolo Dagrada; Silvia Stacchiotti; Elisa Pastore; Alessandro Gronchi; Federica Perrone; Antonino Carbone; Marco A Pierotti; Paolo G Casali; Silvana Pilotti
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

Review 5.  Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model.

Authors:  Haesun Choi
Journal:  Curr Oncol Rep       Date:  2005-07       Impact factor: 5.075

6.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk.

Authors:  L B Harrison; F Franzese; J J Gaynor; M F Brennan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-30       Impact factor: 7.038

7.  Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

Authors:  Suzanne George; Priscilla Merriam; Robert G Maki; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary L Keohan
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Imatinib mesylate in chordoma.

Authors:  Paolo G Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio Crippa; Alessandro Gronchi; Rosaria Orlandi; Carla Ripamonti; Carlo Spreafico; Raffaello Bertieri; Rossella Bertulli; Maurizio Colecchia; Elena Fumagalli; Angela Greco; Federica Grosso; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

9.  Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.

Authors:  Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

10.  Evidence for increased epidermal growth factor receptors in human sarcomas.

Authors:  B Gusterson; G Cowley; J McIlhinney; B Ozanne; C Fisher; B Reeves
Journal:  Int J Cancer       Date:  1985-12-15       Impact factor: 7.396
View more
  3 in total

1.  The molecular biology of soft-tissue sarcomas and current trends in therapy.

Authors:  Jorge Quesada; Robert Amato
Journal:  Sarcoma       Date:  2012-05-10

2.  Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Authors:  Victor Hugo Villar; Oliver Vögler; Jordi Martínez-Serra; Rafael Ramos; Silvia Calabuig-Fariñas; Antonio Gutiérrez; Francisca Barceló; Javier Martín-Broto; Regina Alemany
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

3.  Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma.

Authors:  Xiaoyan Li; Hongjun Gao; Chuanhao Tang; Xiaoqing Liu
Journal:  Onco Targets Ther       Date:  2016-07-29       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.